How dual GLP-1/GIP drugs work

Tirzepatide targets two gut hormones instead of one. This article covers the biology behind that design, what the trial data shows, and where the science remains unsettled.

Tirzepatide is a dual agonist: a single engineered molecule designed to activate both the GLP-1 receptor and the GIP receptor simultaneously. Older drugs in this category, such as semaglutide, activate only the GLP-1 receptor. In the SURMOUNT-1 trial — a large, randomized, double-blind, placebo-controlled study — tirzepatide produced weight loss at all three tested doses (5 mg, 10 mg, and 15 mg weekly) compared to placebo over 72 weeks, with statistically significant differences at every dose. Tirzepatide is FDA-approved for weight management in adults with obesity, or in adults who are overweight with at least one weight-related health condition. It is intended for use alongside a reduced-calorie diet and increased physical activity.

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut after eating. It helps the body manage the influx of nutrients from a meal in several ways. It stimulates the pancreas to release insulin, but only when blood sugar is elevated — a property called glucose-dependent insulin release, which reduces the risk of dangerous blood sugar drops. It also suppresses glucagon, a hormone that raises blood sugar, and slows gastric emptying, which blunts post-meal blood sugar spikes. Finally, it signals brain regions involved in appetite regulation to reduce hunger and promote fullness. These effects produce meaningful reductions in blood sugar and body weight. GLP-1 receptor agonists have been used to treat type 2 diabetes for years and more recently have been approved specifically for weight management. Tirzepatide builds on this mechanism and adds a second target.

GIP (glucose-dependent insulinotropic polypeptide) is also an incretin hormone released by the gut after eating. Like GLP-1, it stimulates insulin secretion in a glucose-dependent way. Beyond that shared function, GIP's role is more complex. It appears to influence fat tissue metabolism and how the body stores and uses energy, though the details of this process in humans are still being studied. For a long time, GIP was considered a less promising drug target than GLP-1. People with type 2 diabetes often show a blunted response to GIP, which made it seem like a limited option for metabolic treatment. More recent research has suggested that the GIP receptor may still be meaningfully activated in certain contexts, and that its effects in the brain and fat tissue may differ from those of GLP-1 in ways that could be clinically useful. That possibility is what made targeting both receptors at once worth pursuing.

Tirzepatide is not two drugs combined. It is a single engineered molecule designed to bind to and activate both the GLP-1 receptor and the GIP receptor. The two receptors are distinct proteins. They share some downstream effects — both stimulate insulin release — but they also have non-identical signaling pathways. Activating both simultaneously may engage appetite regulation, insulin secretion, and fat metabolism through more than one biological route at once. Preclinical data suggest that GLP-1 and GIP agonism may work synergistically, meaning the combined effect could exceed the sum of the two effects separately. These are animal studies, however. Whether and how this synergy translates to humans has not been fully established.

What we don't know: the specific contribution of GIP receptor activation to tirzepatide's effects in humans has not been isolated in clinical studies. We know the drug works. We don't yet know precisely how much each receptor accounts for the results.

The SURMOUNT-1 trial is the primary clinical evidence base for tirzepatide's use in weight management. It enrolled adults with obesity or overweight (without type 2 diabetes) and ran for 72 weeks.

Weight loss

Participants taking tirzepatide at 5 mg, 10 mg, and 15 mg weekly all lost significantly more weight than those taking placebo, with statistically significant differences at every dose.

Cardiometabolic markers

The trial also observed improvements in blood pressure, lipid levels, and blood sugar markers. These are meaningful findings, but the data cannot separate how much came from GLP-1 receptor activation versus GIP receptor activation — the two effects are intertwined in a single molecule.

Comparisons with other drugs

The source materials for this article do not include a head-to-head comparison between tirzepatide and GLP-1-only drugs. Claims that tirzepatide is definitively superior to semaglutide or other single-receptor agents for all patients are not supported by the evidence reviewed here. Individual responses to any medication vary.

Side effects

The most common adverse events were gastrointestinal: nausea, diarrhea, and vomiting, consistent with the broader GLP-1 drug class. These were most frequent during dose escalation and generally decreased over time.

Boxed warning — thyroid tumors

Tirzepatide carries a boxed warning regarding thyroid C-cell tumors, based on rodent studies in which GLP-1 receptor agonists caused such tumors. The relevance of these findings to humans is currently unknown. The warning is precautionary; no human cases have been confirmed.

Contraindications

Tirzepatide should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2).

Combination with other GLP-1 drugs

Tirzepatide should not be used alongside other GLP-1 receptor agonists. Because tirzepatide already activates the GLP-1 receptor, adding another GLP-1 drug duplicates that part of the mechanism — something the prescribing information explicitly advises against.

Pediatric use

Tirzepatide is not approved for use in children. Safety and efficacy in pediatric patients have not been established.

Dose escalation

Treatment begins at 2.5 mg weekly and is gradually increased. This stepwise approach is designed to help the body adjust and to reduce gastrointestinal side effects during the early phase of treatment.

Long-term safety

Long-term safety differences between dual agonists and single GLP-1 agonists have not yet been established. More data will emerge as tirzepatide accumulates a longer track record.

Tirzepatide has a clear clinical evidence base, but several genuine questions remain open.

The GIP contribution

The most significant unknown is how much of tirzepatide's effect comes from GIP receptor activation versus GLP-1 receptor activation. Preclinical data suggest synergy, but the human mechanism has not been mapped in a way that isolates each receptor's contribution. This is not a minor footnote — it is a fundamental question about why the drug works as well as it does.

GIP and cardiometabolic benefits

Some researchers are investigating whether GIP agonism might provide distinct cardiometabolic benefits beyond weight loss. This is plausible based on GIP's known biology, but it requires further research to establish.

Long-term comparative data

Head-to-head safety data comparing dual agonists to single GLP-1 agonists over the long term does not yet exist. That gap is expected to narrow as tirzepatide accumulates a longer track record.

The thyroid question

The human relevance of the rodent thyroid tumor findings remains unknown. No human cases have been confirmed, but the question has not been definitively closed. Research is ongoing.

The questions below are a starting point for a conversation with your doctor or other qualified healthcare provider, not a substitute for one.

Do you have a personal or family history of medullary thyroid carcinoma or MEN 2? If so, tirzepatide is contraindicated.

How does tirzepatide compare to GLP-1-only medications for your specific situation, given what the current evidence does and doesn't show?

What should you expect during dose escalation, and what strategies can help manage GI side effects?

Are you currently taking any other GLP-1 receptor agonists? If so, that combination is not appropriate.

What does a realistic plan look like for the diet and activity changes that are part of the indicated use?

How long might you expect to take this medication, and what follow-up or monitoring is recommended?